Frontlight ResearchEarly access
Not yet taking people in FrancePhase 2
Stopping versus continuing gout medicine in people whose gout is in remission
Compares stopping or keeping urate-lowering pills in adults with gout, guided by ultrasound.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- Amiens Cedex 1, Bobigny, Bordeaux, Brest, Caen Cedex 9, Chambray Les Tours, Corbeil Essonnes Cedex, Creteil, Dijon, La Roche Sur Yon Cedex 9, Lomme Cedex, Nantes Cedex 1, Nice, Paris, Paris Cedex 13, Paris Cedex 18, Reims Cedex, Rennes, Rouen, Saint-Etienne, and Toulouse, FranceSee the 22 sites
- Trial code
- Registry title
- Stop Treatment in gout
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 450 people, planned
- Started
- 3 Feb 2025
- Expected to end
- 3 Feb 2029
- Type of study
- Interventional
- Record updated
- 28 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with gout in remission who take allopurinol or febuxostat. It tests stopping this urate-lowering medicine, with ultrasound checks, against continuing it.
- Age
- 18 years or older
- Sex
- All sexes can join. Women of childbearing age cannot join.
- Disease stage
- Gout defined by the 2015 ACR/EULAR classification criteria. No flares for at least 2 years. No tophi (lumps of urate crystals under the skin).
- Earlier treatment
- Must currently take allopurinol or febuxostat, for at least 2 years. Cannot be on uricosurics (benzbromarone and probenecid) or uricase.
- Biomarker or test result
- Blood uric acid (SUA) level ≤ 60 mg/l. No urate deposit on ultrasound (score 0/24) at both MTPs 1 (big toe joints) and knees.
Main reasons for not taking part
- Unstable serious illness, such as stage IV heart failure, recent heart attack or advanced cancer
- Allergy to allopurinol or febuxostat or their ingredients
- Taking azathioprine or mercaptopurine
- Kidney disease stage 4 (eGFR less than 30 ml/mn/1.73 m2)
- Women of childbearing age
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Age ≥ 18 years
- Gout, defined according to the 2015 ACR/EULAR classification criteria
- No flares for at least 2 years
- No tophi
- Currently receiving allopurinol or febuxostat taken for at least 2 years and SUA levels ≤ 60 mg/l
- No urate deposit on ultrasound (score 0/24) at inclusion visit at both MTPs 1 and knees
- Ability to provide informed consent
- Health Insurance
Who cannot take part
- Ongoing treatment with uricosurics (benzbromarone and probenecid) or uricase
- Unstable systemic medical condition (e.g., New York Heart Association stage IV heart failure, recent myocardial infarction, advanced cancer)
- History of allergy to allopurinol or febuxostat or one of the excipients • Association with
- CKD stage 4 (eGFR less than 30 ml/mn/1.73 m2)
- Women of childbearing age
- Association with azathioprine, mercaptopurine (cytostatics-antimetabolites)
- Contraindications to experimental medicinal products or auxiliary medicinal products
- Patient on SMA (state medical aid-AME)
- Participation in other clinical trial on medicinal product for human use
Where in France
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisBobigny, FranceNot yet recruiting
- Centre hospitalier Universitaire de BordeauxBordeaux, FranceNot yet recruiting
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNot yet recruiting
- Centre Hospitalier Universitaire De Caen NormandieCaen Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Regional Universitaire De ToursChambray Les Tours, FranceNot yet recruiting
- Centre Hospitalier Sud FrancilienCorbeil Essonnes Cedex, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisCreteil, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Centre Hospitalier Departemental VendeeLa Roche Sur Yon Cedex 9, FranceNot yet recruiting
- Groupement Des Hopitaux De L'Institut Catholique De LilleLomme Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire De NantesNantes Cedex 1, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Assistance Publique Hopitaux de ParisParis, FranceNot yet recruiting
- GIE Groupe hospitalier Paris Saint-Joseph/VinciParis, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisParis Cedex 13, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranceNot yet recruiting
- Centre Hospitalier Universitaire ReimsReims Cedex, FranceNot yet recruiting
- Centre Hospitalier Universitaire de RennesRennes, FranceNot yet recruiting
- Centre Hospitalier Universitaire RouenRouen, FranceNot yet recruiting
- Centre Hospitalier Universitaire de Saint EtienneSaint-Etienne, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
About the trial
What the trial wants to find out
to demonstrate that oral ULT withdrawal in patients with gout in remission, monitored with US scans, is not inferior to maintaining oral ULT for the risk of flares at 2 years
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- STING - Maintenance or withdrawal of urate lowering therapy according to ultrasound features in gout patients: a randomised controlled trial
- Plain-language title
- Stopping versus continuing gout medicine in people whose gout is in remissionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 28 August 2026